Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry
We conclude that HER2 IHC3+ tumors have higher frequency of <i>ERBB2</i>_ AMP_CNA and lower frequency of <i>CCND3</i>_ AMP_CNA and <i>MYC</i>_AMP_CNA than IHC2+/ISH+ tumors. These results provide therapeutic strategies in treatment of HER2-positive breast cancer.
Authors
- Yun-Ning Chiu
- Jen‐Hwey Chiu (ORCID: https://orcid.org/0000-0003-3046-6250)
- Ta‐Chung Chao (ORCID: https://orcid.org/0000-0003-1451-1939)
- Chih‐Yi Hsu (ORCID: https://orcid.org/0000-0002-1667-4291)
- Shih‐Hsiang Chou (ORCID: https://orcid.org/0000-0002-3458-9939)
- Ling‐Ming Tseng (ORCID: https://orcid.org/0000-0002-4648-6646)
- Chunyu Liu (ORCID: https://orcid.org/0000-0002-5986-4415)
- Chi‐Cheng Huang (ORCID: https://orcid.org/0000-0003-4378-4776)
- Yi‐Fang Tsai (ORCID: https://orcid.org/0000-0001-7665-0462)
- Yen‐Shu Lin
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Taiwan University (TW)
- Taipei Veterans General Hospital (TW)
- Cheng Hsin General Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/bctt.s507189
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05